[{"address1": "2656 State Street", "city": "Carlsbad", "state": "CA", "zip": "92008", "country": "United States", "phone": "619 728 4760", "website": "https://tyra.bio", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SN\u00c5P, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is TYRA-300, which is in Phase 1/2 clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, thanatophoric dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in Phase 1 clinical trial for bile duct and solid tumors; and TYRA-430 for the treatment of hepatocellular carcinoma. The company was incorporated in 2018 and is headquartered in Carlsbad, California.", "fullTimeEmployees": 49, "companyOfficers": [{"maxAge": 1, "name": "Dr. Todd  Harris Ph.D.", "age": 45, "title": "Co-Founder, President, CEO, Secretary, Treasurer & Director", "yearBorn": 1979, "fiscalYear": 2023, "totalPay": 1065650, "exercisedValue": 0, "unexercisedValue": 4803451}, {"maxAge": 1, "name": "Mr. Alan  Fuhrman CPA", "age": 67, "title": "Chief Financial Officer", "yearBorn": 1957, "fiscalYear": 2023, "totalPay": 763093, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Daniel  Bensen", "age": 48, "title": "Co-Founder & COO", "yearBorn": 1976, "fiscalYear": 2023, "totalPay": 630800, "exercisedValue": 0, "unexercisedValue": 2216617}, {"maxAge": 1, "name": "Dr. Robert L. Hudkins Ph.D.", "age": 68, "title": "Chief Technology Officer", "yearBorn": 1956, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Ronald V. Swanson Ph.D.", "age": 60, "title": "Chief Scientific Officer", "yearBorn": 1964, "fiscalYear": 2023, "totalPay": 536188, "exercisedValue": 0, "unexercisedValue": 298928}, {"maxAge": 1, "name": "Mr. Ali D. Fawaz J.D.", "title": "General Counsel", "fiscalYear": 2023, "totalPay": 629230, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Sarah  Honig", "title": "Vice President of Corporate Development & Strategy", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Liz  Pagano", "title": "Senior Vice President of Human Resources", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Piyush R. Patel Ph.D.", "age": 58, "title": "Chief Development Officer", "yearBorn": 1966, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Douglas  Warner M.D.", "age": 52, "title": "Chief Medical Officer", "yearBorn": 1972, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 6, "boardRisk": 5, "compensationRisk": 8, "shareHolderRightsRisk": 9, "overallRisk": 7, "governanceEpochDate": 1738368000, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 13.17, "open": 13.13, "dayLow": 12.62, "dayHigh": 13.435, "regularMarketPreviousClose": 13.17, "regularMarketOpen": 13.13, "regularMarketDayLow": 12.62, "regularMarketDayHigh": 13.435, "beta": 1.078, "forwardPE": -6.4846992, "volume": 504284, "regularMarketVolume": 504284, "averageVolume": 247318, "averageVolume10days": 277400, "averageDailyVolume10Day": 277400, "bid": 12.4, "ask": 12.91, "bidSize": 200, "askSize": 200, "marketCap": 641140032, "fiftyTwoWeekLow": 12.6, "fiftyTwoWeekHigh": 29.6, "fiftyDayAverage": 15.121, "twoHundredDayAverage": 18.56295, "currency": "USD", "enterpriseValue": 316074016, "floatShares": 10418922, "sharesOutstanding": 50603000, "sharesShort": 2772076, "sharesShortPriorMonth": 2534638, "sharesShortPreviousMonthDate": 1734048000, "dateShortInterest": 1736899200, "sharesPercentSharesOut": 0.0548, "heldPercentInsiders": 0.047470003, "heldPercentInstitutions": 1.02914, "shortRatio": 10.8, "shortPercentOfFloat": 0.1019, "impliedSharesOutstanding": 56215100, "bookValue": 6.852, "priceToBook": 1.8490951, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1727654400, "netIncomeToCommon": -83740000, "trailingEps": -1.61, "forwardEps": -2.02, "enterpriseToEbitda": -3.174, "52WeekChange": -0.34623325, "SandP52WeekChange": 0.19995654, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "TYRA", "underlyingSymbol": "TYRA", "shortName": "Tyra Biosciences, Inc.", "longName": "Tyra Biosciences, Inc.", "firstTradeDateEpochUtc": 1631712600, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "c82a6c3c-220d-350b-9885-606667564179", "messageBoardId": "finmb_650787124", "gmtOffSetMilliseconds": -18000000, "currentPrice": 12.67, "targetHighPrice": 33.0, "targetLowPrice": 28.0, "targetMeanPrice": 30.57143, "targetMedianPrice": 30.0, "recommendationKey": "none", "numberOfAnalystOpinions": 7, "totalCash": 360129984, "totalCashPerShare": 6.811, "ebitda": -99594000, "totalDebt": 6318000, "quickRatio": 29.26, "currentRatio": 29.549, "debtToEquity": 1.744, "returnOnAssets": -0.20209, "returnOnEquity": -0.28656, "freeCashflow": -37571876, "operatingCashflow": -63716000, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2025-02-08"}]